William P. Fay, M.D.
Professor of Internal Medicine and Medical Pharmacology & PhysiologyOffice Location: 306 Cs&E
Office Phone: 573-882-2296
FayW@missouri.edu
Research Interests
- Role of leukocyte-derived tissue factor in thrombosis
- Role of plasminogen activator inhibitor-1 (PAI-1) in the proliferative response to vascular injury
- Mechanisms by which C-reactive protein (CRP) modulates thrombosis
- Role of heme oxygenase-1 in thrombosis
- Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor (TAFI)
Techniques / Methodology:
- Mouse gene targeting
- Rodent models of human vascular disease
- Structure-function studies of blood coagulation proteins
- Thrombosis models
Research Description
Our research laboratory focuses on the roles of the blood coagulation and fibrinolytic systems in vascular disease. We are interested in the molecular processes that determine acute thrombus formation after vascular injury, as well as those that regulate subsequent thrombolysis. We also are interested in how components of the blood clotting and fibrinolytic systems contribute to the pathogenesis of chronic vascular disorders, such as atherosclerosis and restenosis after percutaneous coronary interventions. We study these issues by a variety of experimental approaches, ranging from in vitro studies with purified proteins to intact animal studies. In particular, we rely heavily on murine models of vascular injury and thrombosis, since they enable us to examine the impact of specific genes on complex biologic processes within the living animal. We also are conducting human genetic studies. These projects address the role of plasminogin activator inhibitor-1 as a risk factor for myocardial infarction, and the molecular basis of the variable sensitivity of patients to anticoagulation with warfarin.
Professional Background
- University of Illinois, B.S.
- University of Illinois, M.D.
- Residency in Internal Medicine, University of Michigan Medical Center
- Clinical and Research Fellowship in Cardiovascular Medicine, Mayo Clinic
- Postdoctoral Research Fellow, Howard Hughes Medical Institute
- Assistant Professor of Internal Medicine, University of Michigan
- Associate Professor of Internal Medicine, University of Michigan
Selected Publications
Wu J, Strawn TL, Grunz EA, Lawrence DA, Fay WP: Plasminogen activator inhibitor-1 inhibits angiogenic signaling by blocking cross-talk between αVβ3 integrin and vascular endothelial growth factor receptor-2 (submitted).
Ji Y, Strawn TL, Karkuparthi PR, Grunz-Borgmann EA, Stevenson MJ, Lohman AW, Szalai AJ, Fay WP: C-reactive protein regulates vein bypass graft remodeling (submitted).
Booher AM, Goyal N, Arora N, Froehlich JB, Fay WP: Incidence of bleeding complications in patients receiving aspirin, clopidogrel and warfarin under the supervision of an anticoagulation management service (submitted)
Zuidema MY, Peyton KJ, Fay WP, Durante W, Korthuis RJ., Antecedent hydrogen sulfide elicits an anti-inflammatory phenotype in postischemic murine small intestine: role of heme oxygenase-1., Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H888-94. Epub 2011 Jun 10.PMID: 21666111
Kumar A, Kar S, Fay WP,Thrombosis, physical activity, and acute coronary syndromes.,J Appl Physiol. 2011 Aug;111(2):599-605. Epub 2011 May 19.PMID:21596926
Ji Y, Strawn TL, Grunz EA, Stevenson MJ, Lohman AW, Lawrence DA, Fay WP.,Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts., Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1781-7. Epub 2011 May 12.PMID: 21571686
Fay WP., Linking inflammation and thrombosis: Role of C-reactive protein., World J Cardiol. 2010 Nov 26;2(11):365-9.PMID: 21179303
Wu J, Peng L, McMahon GA, Lawrence DA, Fay WP., Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia., Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1565-70. Epub 2009 Jul 2.PMID: 19574558
Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP., C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance., Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):698-704. Epub 2008 Feb 14.PMID: 18276908
Ahmed A, Stephens JC, Kaus CA, Fay WP., Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin., J Thromb Thrombolysis. 2008 Aug;26(1):44-8. Epub 2007 Nov 6.PMID: 17985084
Garg N, Fay WP.,Plasminogen activator inhibitor-1 and restenosis., Curr Drug Targets. 2007 Sep;8(9):1003-6. Review.PMID: 17896951
Fay WP, Garg N, Sunkar M., Vascular functions of the plasminogen activation system., Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1231-7. Epub 2007 Mar 22. Review.PMID: 17379840
